PNPLA2 and metabolic dysfunction-associated steatohepatitis: Furthermore, reproterol, a potential 17β-HSD13 modulator and FDA-approved drug, was found to greatly attenuate high-fat diet (HFD)-induced NAFLD/NASH by enhancing 17β-HSD13 phosphorylation at Ser33, leading to increased ATGL activity.